FindTrial
Sign In

Low-activity (50 mCi) versus high-activity (100 mCi) radioiodine for post-surgical remnant ablation in differentiated thyroid cancer: a randomized control study

The activity of radioiodine for post-surgical remnant ablation in differentiated thyroid cancer: a randomized control study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003837
Enrollment
Unknown
Registered
2013-07-30
Start date
2013-01-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cancer

Interventions

1:50mCi radioiodine
2:100mCi radioiodine

Sponsors

Nuclear Medicine, Xinhua Hospital of Medical School Shanghai Jiaotong University, Shanghai, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Differentiated thyroid cancer with no clinical, histopathological, sonographical or biochemical signs of persistent disease T1-3N0-1aM0 were included 1-6 months after total thyroidectomy appropriate extent of neck lymph node dissection

Exclusion criteria

Exclusion criteria: Differentiated thyroid cancer with T4,N1b, positive TgAb,or any metastases; patients with liver kidney damage; pregnant breast-feeding women bone marrow suppression.

Design outcomes

Primary

MeasureTime frame
thyroglobulin;Diagnostic radioiodine scan;—

Secondary

MeasureTime frame
absence of remnant tissue and abnormal lymph nodes on neck Ultrasound;—

Countries

China

Contacts

Public ContactHui Wang

Xinhua Hospital of Medical School Shanghai Jiaotong University

wanghuishanghai@hotmail.com+86 021-25078590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026